期刊
MICROBIAL CELL FACTORIES
卷 19, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12934-020-01313-4
关键词
Parkinson's disease; Gut microbiota; Oral microbiota; Nasal microbiota
资金
- Shandong Provincial Natural Science Foundation [ZR2018MH010]
- University Youth Innovation Team of Shandong Province [2019KJK017]
- Shandong Provincial Key Research and Development Program [2018GSF121001]
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease, and in an effort to identify novel therapeutic target for this disease in recent years, human microbiota has attracted much interest. This paper briefly summarizes the main findings concerning the differences of human microbiome across several important mucosal interfaces, including nose, mouth, and gut between PD patients and controls as obtained from a total of 13 studies published since 2015, which covered a total of 943 PD patients and 831 matched controls from 6 countries. Overall, these studies supported the differences of gut microbiota between PD patients and matched controls, while significantly altered bacterial taxa among studies were not identical. Due to relatively limited number of available studies and covered patients, the associations between oral and nasal microbiota and PD remain inconclusive. The therapeutic and diagnostic potentials of gut microbiota for PD are discussed. More well-designed clinical studies recruiting large-scale PD patients are encouraged in future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据